इंडोनेशिया-भारत यांच्या निवेदनात चीनच्या दादागिरीला उत्तर

पीटीआय, जाकार्ता

मुक्त, खुल्या व पारदर्शक नियमांवर आधारित शांततामय इंडो-पॅसिफिक भागाच्या अस्तित्वाची गरज आहे, असे भारत व इंडोनेशिया यांनी म्हटले आहे. सध्या पूर्व व दक्षिण चीन सागरात चीनची दादागिरी सुरू असल्याने दोन्ही आसियान देशांनी प्रथमच सादर केलेल्या संयुक्त निवेदनात करण्यात आलेल्या या उल्लेखाला विशेष महत्त्व आहे.

पंतप्रधान नरेंद्र मोदी व इंडोनेशियाचे अध्यक्ष जोको विडोडो यांनी इंडो-पॅसिफिक क्षेत्रात संयुक्त सागरी सहकार्यावर भर दिला आहे. सागरी सहकार्य तसेच सुरक्षा यांना महत्त्व देताना दोन्ही देशांनी म्हटले आहे, की मुक्त, खुल्या, पारदर्शक, नियमबद्ध तसेच शांततामय भरभराटीचा इंडो पॅसिफिक भाग अपेक्षित आहे. यात शाश्वत विकास, प्रादेशिक एकात्मता, सार्वभौमत्व, परस्पर लाभदायी व्यापार व गुंतवणूक प्रणाली यांचा सन्मान आवश्यक आहे.

चीनने पूर्व व दक्षिण सागरात अनेक ठिकाणी बेटे ताब्यात घेतली असून काही कृत्रिम बेटे तयार केली आहे. प्रवाळ बेटेही चीनने घेतली आहे. चीनने दक्षिण चीन सागरावर दावा सांगितला असताना व्हिएतनाम, मलेशिया, फिलिपिन्स, ब्रुनेई व तैवान यांनी चीनचे दावे फेटाळले आहेत. पूर्व चीन सागरात प्रादेशिक हक्कावरून चीन जपानशी वाद घालत आहे.

पंतप्रधान मोदी व अध्यक्ष विडोडो यांनी सांगितले, की सागरी सहकार्याच्या माध्यमातून शांतता, स्थिरता व आर्थिक वाढ तसेच भरभराट यावर इंडो पॅसिफिक भागात भर दिला जाईल.

इंडो-पॅसिफिकमध्ये ७५०० कि.मी.च्या प्रदेशात भारत मध्यवर्ती ठिकाणी असून इंडोनेशियाची किनारपट्टी १०,८०० कि.मी.ची आहे.

त्यामुळे हिंदी महासागर व पॅसिफिक महासागर यांना जोडणारा हा भाग सामरिक दृष्टिकोनातून महत्त्वाचा आहे. वस्तू, सेवा, गुंतवणूक, तंत्रज्ञान यांच्या मुक्त आदानप्रदानावर इंडोनेशिया व भारत यांनी भर दिला आहे.

२००२ मध्ये मान्य करण्यात आलेली दोन्ही देशांच्या नौदलांची सागरी गस्त वाढवली जाणार असून द्विपक्षीय नौदल कवायती घेतल्या जाणार आहेत.

अटकपूर्व जामिनासाठी चिदंबरम न्यायालयात

पीटीआय, नवी दिल्ली

एअरसेल मॅक्सिस गैरव्यवहारात माजी केंद्रीयमंत्री पी. चिदंबरम यांनी अटकेपासून संरक्षण मागण्यासाठी दिल्ली न्यायालयात दाद मागितली आहे. वरिष्ठ काँग्रेस नेते असलेल्या चिदंबरम यांची अटकपूर्व जामिनाची याचिका विशेष न्यायाधीश ओ. पी. सैनी यांच्यापुढे मांडण्यात आली. नंतर सैनी यांनी चिदंबरम यांना ५ जूनला सक्तवसुली संचालनालयापुढे हजर राहण्याचा आदेश दिला.

सक्तवसुली संचालनालयाने चिदंबरम यांच्यावर ५ जूनला उपस्थित राहण्याचे समन्स आधीच जारी केले आहे. न्यायालयाने सक्तवसुली संचालनालयास नोटीस जारी केली असून ५ जूनपर्यंत उत्तर मागवले आहे. तोपर्यंत चिदंबरम यांच्यावर कुठलीही कठोर कारवाई करण्यात येऊ नये असा आदेश न्यायालयाने दिला.

वरिष्ठ वकील कपिल सिब्बल व अभिषेक मनू सिंघवी यांनी चिदंबरम यांची बाजू मांडताना सांगितले, की माजी मंत्री असलेल्या चिदंबरम यांची पूर्वपीठिका स्वच्छ आहे व समाजात त्यांना एक स्थान आहे, त्यामुळे त्यांना अटकपूर्व जामीन मंजूर करण्यात यावा. चिदंबरम यांच्या याचिकेत म्हटले आहे, की या प्रकरणातील सर्व पुरावे कागदोपत्री असून ते विद्यमान सरकारच्या ताब्यात आहेत, त्यामुळे जप्त करण्यासारखे काही राहिलेले नाही. विशेष सरकारी वकील नीतिश राणा यांनी सांगितले, की चिदंबरम यांच्या अटकपूर्व जामीन अर्जास आमचा विरोध आहे. चिदंबरम हे आज चौकशीस उपस्थित राहिले नाहीत. त्यांना समन्स पाठवण्यात आले होते. न्यायालयाने त्यांचे पुत्र कार्ती चिदंबरम यांना २०११ व २०१२च्या अनुक्रमे केंद्रीय गुन्हे अन्वेषण विभाग व सक्तवसुली संचालनालय यांनी दाखल केलेल्या प्रकरणात १० जुलैपर्यंत अटकेपासून संरक्षण दिले आहे.

GLENMARK PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.
Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of audited financial results for the quarter and year ended 31 March, 2018

(₹ in Millions)

Standalone (Ind AS)

	Particulars (Refer notes below)	Quarter ended 31-03-2018 (Audited) [refer note 10]	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 31-03-2017 (Audited) [refer note 10]	Year ended 31-03-2018 (Audited)	Year ended 31-03-2017 (Audited)
I	Revenue from operations					
	(a) Net sales	15,063.27	14,592.46	19,385.61	60,960.52	76,948.30
	(b) Other operating income	1,614.18	973.03	1,265.26	3,358.32	4,006.70
	Total Revenue from operations	16,677.45	15,565.49	20,650.87	64,318.84	80,955.00
II	Other income	442.98	372.32	(502.49)	1,804.22	1,482.39
III	Total income (I + II)	17,120.43	15,937.81	20,148.38	66,123.06	82,437.39
IV	Expenses					
	(a) Cost of Materials consumed	5,312.54	5,224.70	5,478.75	20,385.67	22,420.13
	(b) Purchase of Stock-in-trade	632.69	891.95	560.33	2,881.77	2,669.96
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	347.33	(304.49)	1.02	518.47	(835.17)
	(d) Employee benefits expense	2,323.30	2,553.98	2,211.26	10,219.21	9,144.71
	(e) Finance costs	507.22	469.99	497.21	1,908.98	1,526.02
	(f) Depreciation and Amortisation expense	298.18	295.53	273.17	1,182.04	1,049.32
	(g) Other expenses	4,758.48	4,531.39	5,678.52	16,838.67	18,568.95
	Total expenses (IV)	14,179.74	13,663.05	14,700.26	53,934.81	54,543.92
V	Profit / (loss) before exceptional items & tax (III-IV)	2,940.69	2,274.76	5,448.12	12,188.25	27,893.47
VI	Exceptional items [Refer note 14]	-	-	2,364.51	-	2,364.51
VII	Profit/(loss) before tax (V - VI)	2,940.69	2,274.76	3,083.61	12,188.25	25,528.96
VIII	Tax expense :					
	Current tax	733.52	489.59	1,462.71	2,706.77	6,040.24
	Deferred tax	(7.95)	(155.99)	(1,949.67)	(661.99)	(1,917.36)
IX	Profit/(loss) for the period (VII - VIII)	2,215.12	1,941.16	3,570.57	10,143.47	21,406.08
X	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss	36.41	(11.92)	35.90	(10.20)	(34.40)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(12.60)	4.12	(12.20)	3.53	11.70
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI	Total comprehensive income	2,238.93	1,933.36	3,594.27	10,136.80	21,383.38
XII	Total comprehensive income attributable to:					
	- Non-controlling interests	-	-	-	-	-
	- Owners of the Company	2,238.93	1,933.36	3,594.27	10,136.80	21,383.38
XIII	Earning Per Share (EPS) (of Re 1/- each) (not annualised)					
	Basic EPS (in Rupees)	7.85	6.88	12.65	35.95	75.86
	Diluted EPS (in Rupees)	7.85	6.88	12.65	35.94	75.84

Consolidated (Ind AS)

	Particulars (Refer notes below)	Quarter ended 31/03/2018 (Audited) [refer note 10]	Quarter ended 31/12/2017 (Unaudited)	Quarter ended 31/03/2017 (Audited) [refer note 10]	Year ended 31/03/2018 (Audited)	Year ended 31/03/2017 (Audited)
I	Revenue from operations					
	(a) Net sales	22,478.93	21,715.05	24,244.14	89,722.32	89,700.86
	(b) Other operating income	319.23	321.57	327.69	1,308.38	2,155.95
	Total Revenue from operations	22,798.16	22,036.62	24,571.83	91,030.70	91,856.81
II	Other income	695.52	(231.64)	(512.87)	914.00	373.65
III	Total income (I + II)	23,493.68	21,804.98	24,058.96	91,944.70	92,230.46
IV	Expenses					
	(a) Cost of Materials consumed	6,149.42	5,051.16	5,189.69	21,501.10	23,548.13
	(b) Purchase of Stock-in-trade	1,734.00	1,862.11	3,606.46	7,547.45	7,191.20
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(40.39)	902.44	(1,026.67)	1,337.12	(4,596.07)
	(d) Employee benefits expense	4,642.73	4,659.42	3,847.40	18,718.41	16,408.06
	(e) Finance costs	743.88	704.74	696.70	2,855.67	2,373.18
	(f) Depreciation and Amortisation expense	735.32	753.84	689.04	3,018.76	2,643.68
	(g) Other expenses	7,044.05	6,334.56	8,516.52	25,772.89	28,938.49
	Total expenses (IV)	21,009.01	20,268.27	21,519.14	80,751.40	76,506.67
V	Profit / (loss) before exceptional items & tax (III-IV)	2,484.67	1,536.71	2,539.82	11,193.30	15,723.79
VI	Exceptional items [Refer note 14]	-	-	809.49	-	809.49
VII	Profit/(loss) before tax (V - VI)	2,484.67	1,536.71	1,730.33	11,193.30	14,914.30
VIII	Tax expense :					
	Current tax	961.43	529.15	1,655.10	3,256.90	6,190.43
	Deferred tax	6.97	(39.87)	(1,762.38)	(102.30)	(2,363.66)
IX	Profit/(loss) for the period (VII - VIII)	1,516.27	1,047.43	1,837.61	8,038.70	11,087.53
X	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss	9.93	(2.84)	29.99	41.96	(47.01)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(9.15)	2.94	(11.46)	(3.25)	13.29
	B (i) Items that will be reclassified to profit or loss	(511.28)	101.42	(2,242.82)	(778.78)	(1,750.00)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI	Total comprehensive income	1,005.77	1,148.95	(386.68)	7,298.63	9,303.81
XII	Total comprehensive income attributable to:					
	- Non-controlling interests	0.47	0.64	(1.17)	0.92	(0.46)
	- Owners of the Company	1,005.30	1,148.31	(385.51)	7,297.71	9,304.27
XIII	Earning Per Share (EPS) (of Re 1/- each) (not annualised)					
	Basic EPS (in Rupees)	5.37	3.71	6.51	28.49	39.29
	Diluted EPS (in Rupees)	5.37	3.71	6.51	28.49	39.28

Consolidated (IFRS)

	Particulars (Refer notes below)	Quarter ended 31/03/2018 (Audited) [refer note 10]	Quarter ended 31/12/2017 (Unaudited)	Quarter ended 31/03/2017 (Audited) [refer note 10]	Year ended 31/03/2018 (Audited)	Year ended 31/03/2017 (Audited)
I	Revenue from operations					
	(a) Net sales	22,478.93	21,715.05	24,244.14	89,722.32	89,700.86
	(b) Other operating income	319.23	321.57	327.69	1,308.38	2,155.95
	Total Revenue from operations	22,798.16	22,036.62	24,571.83	91,030.70	91,856.81
II	Other income	695.52	(231.64)	(512.87)	914.00	372.90
III	Total income (I + II)	23,493.68	21,804.98	24,058.96	91,944.70	92,229.71
IV	Expenses					
	(a) Cost of Materials consumed	6,149.42	5,051.16	5,189.69	21,501.10	23,548.13
	(b) Purchase of Stock-in-trade	1,734.00	1,862.11	3,606.46	7,547.45	7,191.20
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(40.39)	902.44	(1,026.67)	1,337.12	(4,596.07)
	(d) Employee benefits expense	4,642.73	4,659.42	3,847.40	18,718.41	16,408.06
	(e) Finance costs	743.88	704.74	696.70	2,855.67	2,373.18
	(f) Depreciation and Amortisation expense	894.24	895.18	845.28	3,540.67	3,167.61
	(g) Other expenses	7,046.35	6,334.61	8,516.52	25,776.33	28,938.49
	Total expenses (IV)	21,170.23	20,409.66	21,675.38	81,276.75	77,030.60
V	Profit / (loss) before exceptional items & tax (III-IV)	2,323.45	1,395.32	2,383.58	10,667.95	15,199.11
VI	Exceptional items [Refer note 14]	-	-	2,597.59	-	2,597.59
VII	Profit/(loss) before tax (V - VI)	2,323.45	1,395.32	(214.01)	10,667.95	12,601.52
VIII	Tax expense :					
	Current tax	948.64	529.15	1,642.65	3,244.11	6,177.97
	Deferred tax	(135.56)	(68.41)	(2,068.06)	(318.99)	(2,735.66)
IX	Profit/(loss) for the period (VII - VIII)	1,510.37	934.58	211.40	7,742.83	9,159.21
X	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss	9.93	(2.84)	29.99	41.96	(47.01)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(9.15)	2.94	(11.46)	(3.25)	13.29
	B (i) Items that will be reclassified to profit or loss	(463.92)	62.21	(2,304.31)	(696.17)	(1,758.73)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI	Total comprehensive income	1,047.23	996.89	(2,074.38)	7,085.37	7,366.76
XII	Total comprehensive income attributable to:					
	- Non-controlling interests	0.47	0.64	(1.17)	0.92	(0.46)
	- Owners of the Company	1,046.76	996.25	(2,073.21)	7,084.45	7,367.22
XIII	Earning Per Share (EPS) (of Re 1/- each) (not annualised)					
	Basic EPS (in Rupees)	5.35	3.31	0.75	27.44	32.46
	Diluted EPS (in Rupees)	5.35	3.31	0.75	27.44	32.45

Notes:

1. The above results were reviewed by the Audit Committee of the Board at its meeting held on May 28, 2018 and approved at the meeting of the Board of Directors held on 29 May, 2018.
2 The financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016.
3 The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
4 During the quarter, a subsidiary was incorporated viz. Glenmark Pharmaceuticals Singapore Pte. Ltd. The list of subsidiaries as of 31 March, 2018 is provided in Annexure A.
5 The Company operates in one reportable business segment i.e., Pharmaceuticals.
6 As at 31 March, 2018, pursuant to Employee Stock Option Scheme 2003, no options were outstanding. Pursuant to Employee Stock Options Scheme 2016, 5,69,686 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
7 Diluted EPS has been computed considering the effect of conversion of ESOPs and other convertible instruments.
8 Tax expense is computed after considering MAT credit and other income tax benefits.
9 In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have performed an audit of the standalone and consolidated financial results of the Company for the financial year ended 31 March, 2018. There are no modifications in the audit report issued for the said period.
10 The figures for the quarter ended 31 March are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.
11 Post implementation of Goods and Service Tax (GST) with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for quarter and year ended 31 March, 2018 are not comparable with those of previous periods presented.
12 The disclosure of statement of assets and liabilities as per Regulation 33(3)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are an integral part of these results.
13 The Board has recommended a final dividend of 200% .i.e. Rs. 2 per equity share of face value of Re. 1 each for financial year 2017-18. The payment is subject to the approval of the shareholders in the ensuing annual general meeting.
14 "**Exceptional items:** Stand-alone: Exceptional items for the quarter and year ended 31 March, 2017 represents impairment loss relating to investment and trade receivables from the Company's subsidiary in Venezuela. The Company has not received approvals from the Venezuelan government to repatriate any amounts during the year ended 31 March, 2017 and considering the uncertainty around repatriation, the Company believes it's appropriate to impair such investments and trade receivables from the said subsidiary.
Consolidate: Exceptional items for the quarter and year ended 31 March, 2017 represents impairment loss relating to certain intangibles assets under development owing to the Company's future research and development strategy for such products."
15. Previous period's figures have been re-grouped/re-classified wherever necessary.

Glenmark Pharmaceuticals Limited
Annexure A
List of entities included in the consolidated financial results for the year ended 31 March 2018

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. **2.**Glenmark Pharmaceuticals Europe Ltd., U.K. **3.**Glenmark Pharmaceuticals S.R.O. **4.**Glenmark Pharmaceuticals SK, S.R.O. **5.**Glenmark Pharmaceuticals S. A. **6.**Glenmark Holding S.A. **7.**Glenmark Pharmaceuticals S.R.L **8.**Glenmark Pharmaceuticals SP z.o.o. **9.**Glenmark Pharmaceuticals Inc. (formerly Glenmark Generics Inc.) **10.**Glenmark Therapeutics Inc. **11.**Glenmark Farmaceutica Ltda **12.**Glenmark Generics S.A **13.**Glenmark Pharmaceuticals Mexico, S.A. DE C.V. **14.**Glenmark Pharmaceuticals Peru SAC **15.**Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) **16.**Glenmark Uruguay S.A. **17.**Glenmark Pharmaceuticals Venezuela, C.A **18.**Glenmark Dominicana SRL **19.**Glenmark Pharmaceuticals Egypt S.A.E. **20.**Glenmark Pharmaceuticals FZE **21.**Glenmark Impex L.L.C **22.**Glenmark Philippines Inc. **23.**Glenmark Pharmaceuticals (Nigeria) Ltd. **24.**Glenmark Pharmaceuticals Malaysia Sdn Bhd **25.**Glenmark Pharmaceuticals (Australia) Pty Ltd **26.**Glenmark South Africa (pty) Ltd **27.**Glenmark Pharmaceuticals South Africa (pty) Ltd **28.**Glenmark Pharmaceuticals (Thailand) Co. Ltd **29.**Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) **30.**Glenmark Arzneimittel Gmbh **31.**Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) **32.**Glenmark Pharmaceuticals Kenya Ltd **33.**Glenmark Therapeutics AG **34.**Viso Farmaceutica S.L., Spain **35.**Glenmark Specialty SA **36.**Glenmark Pharmaceuticals Distribution s.r.o. **37.**Glenmark Pharmaceuticals Nordic AB **38.**Glenmark Ukraine LLC **39.**Glenmark-Pharmaceuticals Ecuador S.A. **40.**Glenmark Pharmaceuticals Singapore Pte. Ltd.

Mumbai, 29 May, 2018

Glenmark Pharmaceuticals Limited
Balance Sheet as at
(All amounts in million of Indian Rupees, unless otherwise stated)

	STANDALONE		CONSOLIDATED			
	Ind AS As at 31.03.2018 Audited	Ind AS As at 31.03.2017 Audited	Ind AS As at 31.03.2018 Audited	Ind AS As at 31.03.2017 Audited	IFRS As at 31.03.2018 Audited	IFRS As at 31.03.2017 Audited
ASSETS						
Non current assets						
Property, plant and equipment	15,766.49	14,704.96	18,958.10	17,836.97	21,733.74	20,681.23
Capital work-in-progress	3,540.42	2,351.35	9,933.40	6,295.50	10,347.15	6,770.25
Goodwill	-	-	521.04	478.92	521.04	478.92
Other Intangible Assets	1,224.73	1,258.74	10,816.38	9,235.01	13,296.47	12,070.19
Intangible Assets under development	656.33	355.24	1,285.32	785.62	1,285.32	785.62
Financial Assets						
(i) Investments	32,126.84	18,666.99	146.61	156.94	146.61	156.94
(ii) Loans and advances	33,028.48	36,426.84	-	-	-	-
(iii) Other financial assets	380.91	344.70	401.18	362.84	401.18	362.84
Deferred tax assets (net)	6,606.15	5,940.64	13,202.60	13,112.69	12,201.76	11,914.28
Other non-current assets	565.85	447.70	802.23	627.79	389.36	153.05
Total non- current assets	93,896.20	80,497.16	56,066.86	48,892.28	60,322.63	53,373.32
Current assets						
Inventories	11,111.80	11,450.55	20,305.85	21,390.50	20,305.85	21,390.50
Financial Assets						
(i) Investments	-	-	-	-	-	-
(ii) Trade receivables	38,289.08	38,794.04	23,318.07	24,043.20	23,318.07	24,043.20
(iii) Cash and cash equivalents	1,773.82	2,521.78	12,346.91	10,576.59	12,346.91	10,576.59
(iv) Other financial assets	1,937.10	1,836.15	3,856.42	3,581.21	3,856.42	3,581.21
Current tax assets	-	-	-	-	-	-
Other current assets	5,640.71	4,905.78	10,059.67	9,154.89	10,059.67	9,154.89
Total current assets	58,752.51	59,508.30	69,886.92	68,746.39	69,886.92	68,746.39
Total assets	152,648.71	140,005.46	125,953.78	117,638.67	130,209.55	122,119.71
EQUITY AND LIABILITIES						
Equity						
Equity Share capital	282.17	282.17	282.17	282.17	282.17	282.17
Other Equity	103,632.24	94,084.02	51,352.60	44,643.08	55,608.37	49,112.11
Minority interest	-	-	(3.70)	(4.23)	(3.70)	(4.23)
Liabilities						
Non-current liabilities						
Financial Liabilities						
(i) Borrowings	26,860.29	25,893.46	41,417.78	45,363.39	41,417.78	45,363.39
(ii) Other financial liabilities	26.00	24.05	26.00	24.05	26.00	24.05
Deferred tax liabilities (net)	-	-	-	-	-	-
Other non- current liabilities	-	-	-	303.38	-	303.38
Total non-current liabilities	26,886.29	25,917.51	41,443.78	45,690.82	41,443.78	45,690.82
Current liabilities						
Financial Liabilities						
(i) Borrowings	2,950.44	1,871.89	2,950.44	1,871.89	2,950.44	1,871.89
(ii) Other financial liabilities	1,137.36	1,358.42	3,326.27	1,763.94	3,326.27	1,763.94
(iii) Trade payables	15,549.53	14,670.90	18,697.84	17,432.21	18,697.84	17,432.31
Other current liabilities	1,278.69	1,240.90	3,579.74	3,329.30	3,579.74	3,329.30
Provisions	783.58	413.74	4,040.38	2,372.94	4,040.38	2,372.94
Current tax liabilities (Net)	148.41	165.91	284.26	256.55	284.26	268.46
Total current liabilities	21,848.01	19,721.76	32,878.93	27,026.83	32,878.93	27,038.84
Total liabilities	48,734.30	45,639.27	74,322.71	72,717.65	74,322.71	72,729.66
Total equity and liabilities	152,648.71	140,005.46	125,953.78	117,638.67	130,209.55	122,119.71

For and on behalf of the Board of Directors

Glenn Saldanha
Chairman & Managing Director